Loading...
XNASSMTI
Market cap283mUSD
Jan 07, Last price  
32.42USD
1D
-4.11%
1Q
1.06%
Jan 2017
755.41%
Name

Sanara Medtech Inc

Chart & Performance

D1W1MN
XNAS:SMTI chart
P/E
P/S
4.36
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
30.69%
Rev. gr., 5y
61.93%
Revenues
65m
+41.77%
85,019211,167189,755630,505290,183288,021910,4202,209,6851,173,5441,726,3922,632,6433,372,1885,507,8536,304,7415,837,83911,766,76315,586,97624,143,91945,842,84564,989,841
Net income
-4m
L-46.82%
-6,295,335-757,863-623,559-542,756-1,773,196-2,302,527-5,135,491-12,740,816-1,845,323-4,148,088-2,278,177-1,340,455-415,747331,309-600,574-2,930,205-4,382,790-7,305,698-8,092,328-4,303,197
CFO
-3m
L-41.57%
-548,457-624,447-398,970-380,898-1,058,436-1,295,517-1,492,867-343,601-1,226,181-1,821,981-1,686,685-1,202,889409,245-139,862277,142-2,167,401-4,034,518-4,814,526-5,554,870-3,245,556
Earnings
Mar 24, 2025

Profile

Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
IPO date
Apr 07, 1994
Employees
101
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
64,990
41.77%
45,843
89.87%
Cost of revenue
11,985
55,704
Unusual Expense (Income)
NOPBT
53,005
(9,861)
NOPBT Margin
81.56%
Operating Taxes
(5,845)
Tax Rate
NOPAT
53,005
(4,017)
Net income
(4,303)
-46.82%
(8,092)
10.77%
Dividends
Dividend yield
Proceeds from repurchase of equity
911
BB yield
-0.27%
Debt
Debt current
1,303
314
Long-term debt
12,949
1,325
Deferred revenue
Other long-term liabilities
4,665
6,004
Net debt
6,020
(10,405)
Cash flow
Cash from operating activities
(3,246)
(5,555)
CAPEX
(265)
(747)
Cash from investing activities
(10,207)
(3,512)
Cash from financing activities
9,641
(627)
FCF
51,974
(4,060)
Balance
Cash
5,147
8,959
Long term investments
3,084
3,084
Excess cash
4,982
9,751
Stockholders' equity
(28,273)
(23,494)
Invested Capital
87,992
72,037
ROIC
66.24%
ROCE
88.76%
EV
Common stock shares outstanding
8,279
7,907
Price
41.10
-9.67%
45.50
53.98%
Market cap
340,265
-5.42%
359,759
65.83%
EV
346,041
349,247
EBITDA
56,680
(7,490)
EV/EBITDA
6.11
Interest
476
285
Interest/NOPBT
0.90%